Astellas: Vyloy improves survival in patients with advanced gastric cancer
Vyloy plus standard-of-care chemotherapy extended overall survival in patients with advanced gastric cancer. The rate of grade 3 or higher...
AbbVie’s novel epkinly results in meaningful treatment response in patients with treatment-refractory lymphoma
Epkinly showed an overall response rate of 82% with 62.5% of patients achieving complete response. 65% of patients had grade...
Incyte and Syndax: Niktimvo led to significant disease response rates in patients with recurrent chronic graft-versus-host-disease (cGVHD).
All three tested Niktimvo dosing regimens led to statistically significant overall response rates in patients who have undergone allogenic hematopoietic...
Eli Lilly: Kisunla was shown to reduce symptoms and slow disease progression in adults with early symptomatic Alzheimer’s disease.
Compared to the placebo, patients treated with Kisunla had a 35% slower cognitive and functional decline at 18 months of...
J&J: Sirturo significantly improved treatment outcomes in patients with rifampicin-resistant tuberculosis.
83% of participants on an oral Sirturo-containing regimen achieved a favorable outcome compared to 71% of patients on the control...
Johnson and Johnson: The subcutaneous formulation of Rybrevant was more effective than the intravenous formulation in reducing the risk of death in lung cancer patients.
The subcutaneous injectable version of Rybrevant significantly reduced the risk of death compared to intravenous Rybrevant when used in combination...
AstraZeneca and Daiichi Sankyo: Enhertu significantly reduced the risk of disease progression in low and ultra-low HER2 metastatic breast cancer.
In patients with hormone-receptor (HR)-positive metastatic breast cancer and low or ultra-low levels of HER2 expression, Enhertu led to a...
Taysha Gene Therapies: TSHA-102 Gene Therapy Improves Quality of Life in Patients with Rett Syndrome
A patient who received TSHA-102 had durable improvements in motor skills, communication, and socialization. TSHA-102 was well tolerated with no...
Novo Nordisk: Awiqli is a once-weekly insulin injection for patients with type 2 diabetes
Awiqli led to greater glycated hemoglobin (HbA1c) reduction, superior blood sugar reduction, and time spent within the recommended blood sugar...
Novartis: ARV-766 is an androgen receptor degrader efficacious in treating metastatic prostate cancer
In patients with metastatic prostate cancer, ARV-766 treatment led to a greater than 50% reduction in Prostate-Specific antigen (PSA) in...